Puritan Customization Capabilities

Mast Launches New Carbapenemase Detection Set

Carbapenemase Detection Set
Mast is pleased to announce the launch of a NEW Carbapenemase Detection Set, the latest innovative product in its hugely successful Antibiotic Resistance Detection Set portfolio.

The emergence and dissemination of carbapenem-hydrolysing Ss-lactamase enzymes over the last decade poses a serious threat to public healthcare. Of special concern is the broad spectrum of resistance harboured by carbapenemase producing Enterobacteriaceae, severely limiting therapeutic options. Accordingly, there remains a need to rapidly identify carbapenemase producers to guide appropriate antibiotic usage, and prevent the development of outbreaks1.
Mast's Carbapenemase Detection Set provides a reliable phenotypic identification of metallo Ss-lactamases (MBL) and Klebsiella pneumoniae carbapenemases (KPC), with 100% sensitivity for NDM-1, whilst differentiating KPC positive isolates from those expressing ampC coupled with porin loss.

Minimum inhibitory concentrations (MICs) are notoriously variable in carbapenemase producing isolates2, further supporting David Livermore's argument that it is invaluable to directly seek carbapenemases to deliver effective antibiotic management policies.

Using a combination disc technology incorporating specific enzyme inhibitors to positively detect resistant enzymes, discs are manufactured as 'matched pairs' to prevent erroneous results arising from variation in content providing a comprehensive, reliable and cost-effective test.

This simple 4-disc system is available in a convenient cartridge format, compatible with any Mast DiscMaster dispenser, streamlining work flow and assisting smooth integration into routine laboratory testing.


  1. Nordmann, P., Poirel, L. Strategies for identification of carbapenemase-producing Enterobacteriaceae. J Antimicrob Chemother 2013 68: 487-489

  2. Livermore, D.M., Andrews, J.M., Hawkey, P.M., Ho, P.L., Keness, Y., Doi, Y.. et al. Are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly? J Antimicrob Chemother. 2012;67:1569-77

NOTE: This item is from our 'historic' database and may contain information which is not up to date.

Source : Mast Group Ltd. View Company Information

Posted on March 11, 2013